| Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. | |
| | |
MedLine Citation:
|
PMID: 9316529 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: This study tested the hypothesis that metoprolol restores the reduction of the inotropic effect of the cyclic adenosine monophosphate (cAMP)-phosphodiesterase inhibitor milrinone, which is cAMP dependent but beta-adrenoceptor independent. BACKGROUND: Treatment with beta-adrenergic blocking agents has been shown to lessen symptoms and improve submaximal exercise performance and left ventricular ejection fraction in patients with heart failure. Restoration of the number of down-regulated beta-adrenoceptors has been suggested to be one mechanism of beta-blocker effectiveness. However, the reversal of postreceptor events, namely, an increase in inhibitory G-protein alpha-subunit concentrations, could also play a role. METHODS: Fifteen patients with heart failure due to dilated cardiomyopathy (left ventricular ejection fraction 24.6 +/- 1.5% [mean +/- SD], New York Heart Association functional class II or III) were treated with metoprolol (maximal dose 50 mg three times daily) for 6 months. Before and after metoprolol treatment, inotropic responses to milrinone (5 to 10 micrograms/kg body weight per min) were measured echocardiographically. For comparison, responses to milrinone were determined under control conditions and after accelerated application of 150 mg of metoprolol to inactivate beta-adrenoceptors in subjects with normal left ventricular function. RESULTS: In subjects with normal left ventricular function, treatment with metoprolol did not alter the increase in fractional shortening or pressure/dimension ratio of circumferential fiber shortening after application of milrinone. In patients with heart failure, treatment with metoprolol significantly increased left ventricular ejection fraction, fractional shortening and submaximal exercise tolerance and reduced heart rate, plasma norepinephrine concentrations and functional class. After metoprolol treatment, milrinone increased fractional shortening but had no effect before beta-blocker treatment. CONCLUSIONS: Milrinone increases inotropic performance independently of beta-adrenoceptors in vivo. Metoprolol treatment restores the blunted inotropic response to milrinone in patients with heart failure, indicating that postreceptor events (e.g., increase in inhibitory G-protein) are favorably influenced. This mechanism could contribute to the beneficial effects observed in the study patients and represents an important mechanism of how beta-blocker treatment influences the performance of the failing heart. |
| | |
Authors:
|
M Böhm; H J Deutsch; D Hartmann; K L Rosée; A Stäblein |
Related Documents
:
|
22473019 - Blood pressure and heart rate predict outcome in patients acutely admitted with suspect... 22071819 - Creatine and creatine analogues in hypertension and cardiovascular disease. 22434219 - Assessment and management of aortic valve disease in patients with left ventricular dys... 21934609 - Plasma myeloperoxidase concentration predicts the presence and severity of coronary dis... 21959129 - Clinical outcomes based on completeness of revascularisation in patients undergoing per... 22292869 - Apixaban for the prevention of stroke in atrial fibrillation. 17878729 - Frequency and significance of cardiac sources of embolism in the toast classification. 19008149 - Clinical trials update from european society of cardiology meeting 2008: time-chf, bach... 15921789 - Tissue doppler velocities of mitral annulus and nt-probnp in patients with heart failure. |
Publication Detail:
|
Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 30 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 1997 Oct |
Date Detail:
|
Created Date: 1997-10-30 Completed Date: 1997-10-30 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 992-6 Citation Subset: AIM; IM |
Affiliation:
|
Klinik III für Innere Medizin, Universität zu Köln, Cologne, Germany. michael.boehm@medizin.univ.koeln.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
therapeutic use* Adult Aged Cardiomyopathy, Dilated / complications Cardiotonic Agents / therapeutic use* Drug Synergism Female GTP-Binding Protein alpha Subunits, Gi-Go / drug effects Heart Failure / drug therapy*, etiology, ultrasonography Humans Male Metoprolol / therapeutic use* Middle Aged Milrinone Myocardial Contraction / drug effects Phosphodiesterase Inhibitors / therapeutic use* Pyridones / therapeutic use* Receptors, Adrenergic, beta / drug effects Receptors, Cyclic AMP / drug effects Stroke Volume / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Cardiotonic Agents; 0/Phosphodiesterase Inhibitors; 0/Pyridones; 0/Receptors, Adrenergic, beta; 0/Receptors, Cyclic AMP; 37350-58-6/Metoprolol; 78415-72-2/Milrinone; EC 3.6.5.1/GTP-Binding Protein alpha Subunits, Gi-Go |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients w...
Next Document: Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle w...